ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
•10 Feb 2025 14:16

Get Nice Financial (1469 HK)'s Scheme Vote On The 7th March

As of the 14th Feb, GNH is no longer shortable. Avoid the arb trade. A more interesting bet is GNH, at a 74% discount to NAV and 0.21x P/B. That...

Logo
403 Views
Share
bullish•Fosun Tourism
•10 Feb 2025 09:00

Fosun Tourism (1992 HK)'s Scheme Buyback Vote On The 4th March

This is a clean deal. Assuming payment early April, I'd pay up to HK$7.67/share for a gross/annualised return of 2%/15%.

Logo
431 Views
Share
•09 Feb 2025 08:30

APAC Healthcare Weekly (Feb 9)- Daiichi Sankyo, Astellas, SanBio, IHH, Henlius Biotech, Dr. Reddy’s

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Logo
827 Views
Share
bullish•Fuji Soft Inc
•09 Feb 2025 06:15

(Mostly) Asia-Pac M&A: Shibaura, Tecnos, Insignia Fin., Fosun Tourism, Fuji Soft, Shin Kong/Taishin

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
616 Views
Share
•05 Feb 2025 13:35

Pentamaster (1665 HK): 28th Feb Vote On Parent's Offer

This looks done. If small illiquid arbs are your bent, I'd pay up to HK$0.98/share for a gross/annualised return of 1.9%/15%. Currently trading at...

Logo
515 Views
Share
x